...
首页> 外文期刊>Archives of gynecology and obstetrics. >Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
【24h】

Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.

机译:IB2期,IIA期大块宫颈癌的治疗:新辅助化疗,根治性子宫切除术和原发性根治性子宫切除术的单机构经验。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: The aim of this study was to compare the efficacy and safety of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (NAC group) with primary radical hysterectomy (RH group). METHODS: We reviewed all patients with bulky stage IB-IIA cervical cancer treated at Seoul National University Hospital from January 1, 2000 to December 31, 2006. Thirty-three patients were treated with NAC prior to radical hysterectomy, and 41 patients were treated with radical hysterectomy. RESULTS: Clinical characteristics were not significantly different between the two groups. The response rate in the NAC group was 81.8%. Operation time, estimated blood loss, and complication rate were not significantly different between the two groups. Pathologic outcomes were improved in the NAC group. Adjuvant therapy was less frequently performed in the NAC group (51.6%) than in the RH group (82.9%) (P = 0.005). The 5-year progression-free survival was 90.7% in the NAC group and 81.3% in the RH group, but the difference was not statistically significant (P = 0.297). CONCLUSION: The results of this study suggest that NAC may improve pathologic outcomes, decrease the need for adjuvant radiation therapy and have a comparable operation feasibility without affecting progression-free survival.
机译:引言:本研究的目的是比较新辅助化疗(NAC),行根治性子宫切除术(NAC组)与原发性根治性子宫切除术(RH组)的疗效和安全性。方法:我们回顾了从2000年1月1日至2006年12月31日在首尔国立大学医院接受治疗的所有患有IB-IIA期宫颈癌的患者。33例行根治性子宫切除术的患者接受了NAC治疗,其中41例接受了全子宫切除术子宫全切除术。结果:两组的临床特征无明显差异。 NAC组的回应率为81.8%。两组的手术时间,估计失血量和并发症发生率无显着差异。 NAC组的病理结果有所改善。与RH组(82.9%)相比,NAC组(51.6%)的辅助治疗频率较低(P = 0.005)。 NAC组和RH组的5年无进展生存率分别为90.7%和81.3%,但差异无统计学意义(P = 0.297)。结论:这项研究的结果表明,NAC可以改善病理结果,减少辅助放射治疗的需要,并且在不影响无进展生存的情况下具有可比的手术可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号